Vision Loss News and Research

RSS

Researchers reveal why Peel has one of highest rates of diabetes in Ontario

According to researchers at St. Michael's Hospital, there are two significant reasons why Peel has one of the highest rates of diabetes in Ontario: neighbourhood design that discourages walking and a population with many residents whose ethnic backgrounds predispose them to diabetes.

11 Apr 2014

Occasional drinking and physically activity linked with reduced risk of developing visual impairment

A physically active lifestyle and occasional drinking are associated with a reduced risk of developing visual impairment, according to a study published online this month in Ophthalmology, the journal of the American Academy of Ophthalmology.

19 Mar 2014

Study: Just a fifth of people with hearing problems use hearing aid

Just a fifth of people with hearing problems wear a hearing aid, a study by The University of Manchester has found.

From The University of Manchester 18 Mar 2014

Research explores new diagnostic strategies to detect glaucoma

Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it.

7 Mar 2014

Cataract surgery followed by use of contact lenses may be better solution for infants

For adults and children who undergo cataract surgery, implantation of an artificial lens is the standard of care. But a clinical trial suggests that for most infants, surgery followed by the use of contact lenses for several years—and an eventual lens implant—may be the better solution.

7 Mar 2014

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare.

3 Mar 2014

Study establishes innovative approaches to improve vision of young children with brain tumor

Robert Avery, DO, MSCE, of Children's National Health System and colleagues are establishing innovative approaches with technology and medication to improve the vision of young children who have visual pathway glioma, a type of brain tumor.

3 Mar 2014

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Ophthotech Corporation today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.

27 Feb 2014

UAB launches pilot program to detect earlier stages of glaucoma

Glaucoma is a silent disease. It does not hurt, symptoms are slow to develop, and most people do not notice any loss of vision until it is too late. A project by ophthalmologists at the University of Alabama at Birmingham will examine whether a partnership with community-based optometrists will improve detection and treatment of glaucoma, especially for high-risk populations.

27 Feb 2014

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

Ellex gets CE Mark approval for 2RT laser treatment of early stage AMD

Ellex Medical Lasers Limited, a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that it has secured a CE Mark (Conformité Européenne) for its proprietary Retinal Rejuvenation Therapy (2RT) laser treatment of early Age-Related Macular Degeneration (AMD).

24 Feb 2014

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.

13 Feb 2014

Researchers examine link between gender and genetic disorder

A genetic disorder that affects about 1 in every 2,500 births can cause a bewildering array of clinical problems, including brain tumors, impaired vision, learning disabilities, behavioral problems, heart defects and bone deformities. The symptoms and their severity vary among patients affected by this condition, known as neurofibromatosis type 1 (NF1).

9 Feb 2014

Human visual system can retain plasticity even after extended blindness

Deprivation of vision during critical periods of childhood development has long been thought to result in irreversible vision loss.

28 Jan 2014

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Using a novel high-throughput screening process, scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma.

24 Jan 2014

Clues of "silent thief of sight”: Glaucoma

Glaucoma is sometimes called the "silent thief of sight" because it slowly damages the eyes and can cause irreparable harm before there is any vision loss. But this disease is stealthy in more ways than one.

22 Jan 2014

Gene therapies correct three forms of retinal degenerative diseases

Gene therapies developed by University of Pennsylvania School of Veterinary Medicine researchers have worked to correct different forms of blindness. While effective, the downside to these approaches to vision rescue is that each disease requires its own form of gene therapy to correct the particular genetic mutation involved, a time consuming and complex process.

17 Jan 2014

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients.

16 Jan 2014

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients. With this new knowledge, investigators aim to accelerate the process of healing and repair in damaged corneas to ultimately reverse the effects of diabetes-induced eye complications.

15 Jan 2014

Residual structures in brain play key role in restoring vision in stroke patients

Scientists know that vision restoration training (VRT) can help patients who have lost part of their vision due to glaucoma, optic nerve damage, or stroke regain some of their lost visual functions, but they do not understand what factors determine how much visual recovery is achieved.

6 Jan 2014

Vision Loss News and Research

Researchers reveal why Peel has one of highest rates of diabetes in Ontario

Occasional drinking and physically activity linked with reduced risk of developing visual impairment

Study: Just a fifth of people with hearing problems use hearing aid

Research explores new diagnostic strategies to detect glaucoma

Cataract surgery followed by use of contact lenses may be better solution for infants

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Study establishes innovative approaches to improve vision of young children with brain tumor

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

UAB launches pilot program to detect earlier stages of glaucoma

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Ellex gets CE Mark approval for 2RT laser treatment of early stage AMD

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Researchers examine link between gender and genetic disorder

Human visual system can retain plasticity even after extended blindness

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Clues of "silent thief of sight”: Glaucoma

Gene therapies correct three forms of retinal degenerative diseases

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Residual structures in brain play key role in restoring vision in stroke patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News